What are the best ways to prepare antigen/antibody reagents with highest HCP coverage?
|
|
- Audrey White
- 5 years ago
- Views:
Transcription
1 What are the best ways to prepare antigen/antibody reagents with highest HCP coverage? Regulators remained agnostic on technical approaches so long as the all of the HCP ELISA reagents are demonstrated to perform as necessary for the assay s intended use (monitor any HCPs that can potentially end up in purified DS). Regulatory acceptance of HCP ELISAs will be driven by the data sponsors will provide on your HCP immunoreagents and assays. Draft USP and EP general chapter contain information on various ways to produce/characterize HCP immunoreagents based on experiences of the pharmacopeial HCP committee members. (*SEE SLIDES TMS/KH). It was noted that compendial chapters have different legal implications in different regions of the world, so sponsors should consult their regulatory authorities for any potential impact on their HCP ELISA development and validation strategies. There was no single immunological approach to guarantee complete coverage of total population of HCPs by anti-hcp antibody preparations. Combinations of approaches have been used successfully by numerous sponsors, with major technical improvements made in the last decade. Various strategies debated in the preparation of the HCP immunogen included using complete cellular lysates vs just the extracellular soluble fractions, using upstream or downstream material, using upstream and downstream material, using either or both US/DS material separated into HMW and LMW immunogen fractions, using bound HCPs stripped from process chromagraphy steps, using cascade immunization to enrich anti-hcp Pabs. Questions arose regarding the suitability of using HCP material from null construct cultures which may not fully mimic actual process conditions for the expressed proteome. Elements that might alter the proteome (either the core protein or the PTMs) include age of cultures (eg early vs EOP cultures) as well as the edges of upstream process ranges. Another concern was if API has any impact on differential expression and/or co-purification of HCPs, then a null construct might be deficient in or have a slightly different population of HCPs. To assess the impact (or not) of these elements, it was suggested that HCP populations from different process runs should be analytically compared to de-risk the source(s) of the HCP immunogen. Various comparative methods were mentioned (MS fingerprint, silver or sypro stained gels, 2DIGE comparison of null vs actual cell culture). Several attendees indicated they use multiple types of HCP materials as separate immunogens to allow them to evaluate and pool the most reactive antisera for subsequent puification as the ELISA immunoreagents. It was noted that even if separate materials were used to generate anti-hcp antisera. the HCP ELISA reference standard should be a total HCP mixture (ie reflecting the HCP proteome),.
2 What are the best ways to prepare antigen/antibody reagents with highest HCP coverage (contt d)? Whether using a single immunogen or separate immunogens, evaluating serum from individual animals than pooling high titer antisera from multiple animals to achieve desired reactivity was reported to have been very successful in producing higher coverage anti-hcp reagents. Mentioned, but not further discussed, was the possibility of generating then pooling antisera generated in different species to produce dual-species HCP immunoreagents. The pros and cons of different approaches on preparation of purified polyclonal antibodies from antisera were also discussed. Currently the two major strategies are 1) affinity-purification of total Igs (ie over Protein A or G affinity columns), or 2) affinity purification of only anti-hcp Igs over HCP columns. The former yields an immunoreagent with only a proportion of specific anti-hcp Pabs and with a higher possibility for cross-reactivity of non-hcp Pabs to the API. The latter yields an active set of anti-hcp Pabs but the Pabs recovered are totally dependent on the nature of the HCP material used on the column (if an HCP wasn t on the column, that anti-hcp Pab won t be in the immunoreagent). Regardless of immunization or purification strategy, both regulators and industry considered it vital to fully characterize the immuno-specificity of the resulting anti-hcp Pab immunoreagent. Key characterization elements were 1) assessing non cross-reactivity with the API protein, 2) assessing the ability to detect low-abundance and/or low HCP MW species, 3) assessing detection of any sub-population of HCPs that are enriched in downstream steps, and 4) demonstrating the percentage of the total HCP proteome of the expression system that the Pab can detect. 2D gels/blots are currently the gold standard with regulators to show the degree of immuno-recognition of the anti-hcp Pabs with the total HCP population. It was acknowledged that 2D gels and blots may miss some HCP Ag/Ab binding reactions because: 1) the gels typically reduce and denature the HCPs, losing any epitopes that are solely conformational (although it was mentioned that conformational-only epitopes could be a small subset of total HCP epitopes), and 2) for each HCP and Pab reagent set, the gel/blot conditions require experimental optimization of each step to achieve accurate results. To supplement 2D gel/blot specificity data, it was encouraged to characterize HCP ELISA reagents with orthogonal means of assessing immunoreactiviy such as 2D HPLC and Antibody Affinity Extraction (AAE). It was noted that since these analytical characterization data sets validate the immuno-specificity of the HCP ELISA, they should be referenced (and are increasingly being included) in HCP ELISA method validation packages. Main goal: Producing (by any immunological means necessary) broadly specific HCP immunoreagents for a given expression system in an given process, then accurately establishing what those immunoreagents detect vs what they miss of the HCP proteome in production cells.
3 How to best replenish and bridge these critical reagents? It was highly recommended that the preparation and characterization of HCP ELISA reagents (immunogen, antisera and Pabs) are thoroughly documented with sufficient technical details to allow them to be re-created as supplies become depleted.over time in the life cycle of the product. One note made from discussions was that if old in-house HCP ELISA reagents exist from past products, they should be checked for specificity for use in new products. The ideal scenario is to avoid having to replenish such complex protein mixtures by preparing enough HCP immunogen and anti-hcp Pabs to last through planned product lifetime. If this is not possible (eg with ongoing platform processes, or late phase or legacy products), it will be necessary to do sufficient analytical characterization of the immunogens and antibodies to show comparability to the original reagents for detecting and quantifying HCPs. It may also be necessary to test representative DS lots using the old vs new HCP ELISA reagents to assess the impact on DS HCP results, but only after the new reagents have been characterized for degree of comparability to the old reagents.. Even process-specific immunoreagents should be assessed for comparable sensitivity and specificity to assure continuity of data with prior reagents. An FDA case study was presented where a deficient new Pab reagent was not acceptable in assuring continued product quality and consistency for HCPs. Since an ELISA signal is a sum of all immunoreactions in the wells; the same value can come from different reactions; ie if a signal reads as100 ppm, is it from 2 x 50 ppm each, or 10 x 10 ppm each?) So ELISA alone is not capable of assessing the comparable heterogeneity of mixed populations of immunoreagents (Ag or Ab). Therefore the bridging of new HCP immunoreagents requires more than just testing the new batches in the ELISA itself. Bridging of old vs new HCP immunoreagents requires approaches that can compare the pattern and abundance of HCPs in the ELISA reference standard, and/ or the immunospecificity of the Pabs (whichever reagent was changed, or both). How should bridging studies be done between HCP assays? What are the expectations for such studies? When should they be done? Bridging the historical HCP data obtained with commercial HCP ELISA to data generated with new process-specific HCP ELISA reagents is also a critical exercise prior to finalizing HCP specifications for BLA/MAA. Typically this is done by re-testing numerous DS batches (especially all batches used in the clinic)with the new process-specific HCP ELISA to obtain more accurate values for residual HCPs. Similarly, some reported that their process clearance studies done with commercial HCP ELISAs may be re-assessed if a more specific process-specific HCP ELISA is developed.
4 How does one determine the suitability of HCP assays at different stages of product lifecycle? During development, when should a change be made from generic commercially available assay to the specific HCP assay? At a minimum, use an approach like 2D gels/blots to assess the specificity to your HCP proteome of the commercial ELISA immunosreagents (or immunoreagents from an existing in-house HCP ELISA ) as soon as you start using it to know what you won t know from using that ELISA. One attendee also mentioned cases of commercial HCP ELISA reagents that cross reacted with some APIs but not others in their program, confirmed by doing 1D gel/blots (reduced and non-reduced, native and denatured). It was discussed that it is wise to assess crossreaction to API before using any HCP ELISA. Hindsight has showed using process-specific ELISA as early as possible is best means to de-risk process development R&D studies missing several HCPs. You can only truly optimize the DS process steps with accurate measurement of HCPs, otherwise you will be making changes with partial data on total HCP shifts within the manfuacturing process steps.. Discussions brought up case studies that have shown inaccurate characterization of HCPs in process clearance steps can have impact on timelines if suddenly finding something not previously detected that is problematic to product and requires another round of process improvements. If using an interim HCP ELISA, it is critical to archive all DS samples tested with it for retesting with final HCP ELISA. Depending on what is detected (or not) by the early phase HCP ELISA, you may be able to use throughout development, particularly if the ELISA is supplemented with other reagent-independent HCP analytical tools in process and product characterization and comparability studies. What HCP comparability studies should be done to support process changes? Sometimes generic ELISA might not be able to detect the same signals in upstream vs downstream ELISAs ; sometimes difference ELISAs detect different populations in the same products (Sandoz data with originator vs biosimilar). In process comparability studies, best practices are to balance risk of missing HCPs by ELISA by utilizing the analytical power of broad-based reagent -ndependent characterization of process and product (eg MS, 2DIGE)
5 Discussion points on the state-of-the art analytical control strategy for HCP: Are immunoassays still the most suitable method for QC testing of HCPs? US, HC and EU regulators answers: Currently HCP ELISAs are the gold standard for QC testing of DS for release. ELISAs generate a summed HCP response for the samples so you can t see which HCPs are there or not, but it provides a simple method for QC operations and a single value for specification limits. How to overcome dilution-related linearity issues in immunoassays with broad HCP coverage? This is the most technically challenging aspect of using highly diverse set of Pabs in a single ELISA well. (See Marty V s excellent cartoon). This is seen as hook effect in assay dilution series where lower dilutions give higher readings. HCP ELISA developers need to experimentally evaluate this phenomenon for each assay and validate the minimal valid dilution (refer to the USP HCP chapter explanation of how to do MVD). What other technologies are being used for GMP release testing for HCPs? US, HC and EU regulators answered any technology is possible if sponsors can demonstrate it accurately and sensitively measures HCPs and can be validated for reliable performance. MS is very information rich tool on HCPs (can see specific proteins and directly identify them), but may be too complex of technology for QC; Other technologies are mostly used for characterization of the QC assay as well as investigation of issues with the product/process.; some may evolve into QC uses over time. Under what circumstances is more than one QC release assay needed to measure HCPs? This could be necessary for specified HCPs like PLBL2 that are known to co-purify with DS, or other HCP sub-populatons that are residual at high abundance in DS (eg highly abundant milk proteins in DS from transgenic animals that swamp out the HCP signal from others that are at lower levels). Although in such cases sponsors might develop sufficient process characterizaton data to monitor in process vs in QC release (data driven for process control/consistency) What are the characterization assays that support the selection, development, and validation of the QC assay? What is the role of Mass Spectrometry? Clearly MS methodologies are emerging as powerful tools in HCP characterization for process and product, and assessing comparability of process change; investigating problems with HCP assays and HCP immungenicity issues Not clear yet whether MS will also become valuable in comparability of originator to biosimilar products, although preliminary data have shown promise in assessing patterns of HCPs in biosimilar products vs originator products (Health Canada Yves Aubin)
6 Which experiences do the regulators have with HCP characterization, testing, and control that are the basis for their current concerns and expectations? What are the regulators decision processes for evaluating the clinical risk of HCPs? What are the risks with HCPs present in clinical trial batches that initially went undetected? In commercial batches? Finding HCPs in clinical batches after those batches have been in patients (eg with a more specific HCP ELISA) is less risky than finding new HCPs in batches that have never been in clinical trials because the HCPs were already shown to be no short-term safety risk (although long term immunogenicity is unknown). For commercial products, HCP populations must be thoroughly compared before and after DS process changes to avoid surprises in the new process DS lots..for comp studies, reagent-independent techniques can be most powerful esp for comparing HCPs in process intermediates. What is the regulators thinking about routinely monitoring anti-hcps antibodies during clinical development? CBER: For replacement therapies for plasma proteins (high concentration and frequent dosing), Office of Blood Products is currently telling sponsors to develop clinical immunogenicity assay for screening anti-hcp Abs at Phase 1. Testing patients for anti-hcp antibodies (as well as the major focus of anti-drug antibodies, ADA). This is in parallel with the using an HCP ELISA for product QC testing (commercial in early phase, custom in late phase). CDER: ADA immunogenicity assay needed by ph 1 but would require anti-hcp assay on case by case basis; the risk assessment would be based on the principles of the draft FDA guidance on immunogencity of therapeutic proteins HCP spec is finalized after process validation based on clinical ranges and demonstrated process consistency. In some cases, routine HCP testing of each DS lot might be waived after commercial manufacturing consistency (eg10 to 30 lots commercial product) What are the regulators current thoughts on establishng a commonly acceptable HCP limit in biotech/biosimilar products? There are NO common HCP limits that can be officially set for all products due to multiple factors that are unique for each product: Primarily it is based on target indication for product (dose, route) and clinical purpose (replacement vs acute). Add to that the variances in HCP test method analytical capability (specificity, sensitivity), and variable process capabilities (more vs less robust clearance steps). Finally, not all HCPs are equally problematic: speaker examples showed where one specific protein caused problems in some products, while some cases rather high levels of HCPs have not been a problem in many legacy protein products. For these same reasons, with biosimiilars it is not possible to simply compare HCPs to HCP levels in similar products on the market. CBER: wide range of limits (low ng to low ug) in different units (ppm, ng/mg, ng/u) so not possible to set one limit value PEI: Limit of 1 ng/mg or less has been show to be possible for Mab products; other therapeutics generally propose NMT 100 ppm in early development
7 Regulatory authorities HCP assays are currently the weakest analytical link in the total characterization and control strategy for biotech and biosimilar products Excellent presentations by US and EU regulatory agencies for therapeutic and biologic products in both regions. All reg speakers listed the specific rules and guidance docs with which they are obligated to review HCPs. Please be sure all of these reg refs are in the final summary paper. Also please confirm that all reg slides are on the CaSSS website archives to accompany the paper (and point readers to these slides with the URL). Are there common HCPs that should be of particular concern in a given class of products (e.g. Monoclonal Antibodies, Coagulation Factors)? Are there common HCPs in a given cell line that should be specifically checked for when developing a product in that cell line? Speakers from academia and industry gave excellent examples of a wide variety of HCP issues observed with different types of products. (refer to speaker slides to be posted on CaSSS website for specific details). Also note that in many speaker slides were specific citations to papers on the work being presented, or similar HCP issues previously published. Review speaker slides for these useful reference articles. Along with the case studies presented, attendees (industry and regulatory) had many anecdotal candidates, but no combined list of these is available publically (yet:..?) PLBL2 in CHO (soon to be published); others have been published or presented HCP proteases (several publications) have been shown to have impact on product quality Non-Mab products in human cell line have showed co-purification of HCPs Even from the same cell line different enzymatic protein products showed different hitch-hiker HCPs Biologically, chaperones are high targets for co-purifying proteins Cytokines products should screen DS for co-purifying HCPs that are also cytokines Certain cell culture systems over-express certain host proteins Process affinity resins have been shown to pick up and enrich HCPs Transgenic systems have highly abundant proteins in the HCP mixture that may need special attention to monitoring Novel expression systems (modification of a conventional cell type) have shown specific differences in HCPs Request to CaSSS: Can the co-leads and speakers pull together all of the HCP case studies shown (and cited) by the presenters (esp regulators) and present the list in a side-bar table in the Forum white paper for readers to see? And where publications are available for them, please include the citations in the summary paper.
FDA HCP assays are current the weakest analytical link in the total control strategy for biotech products
FDA HCP assays are current the weakest analytical link in the total control strategy for biotech products What are the best ways to prepare antigen/antibody reagents with highest HCP coverage? There was
More informationAffigenix Biosolutions Private Ltd, 265/ 1F, KSSIDC Industrial Area Bangalore, Karnataka,India
Host Cell Protein & Other Impurity Clearance Assays for Biosimilar Development Omics Biowaivers, Biologics & Biosimilars- Oct 29, 2014 Affigenix Biosolutions Private Ltd, 265/ 1F, KSSIDC Industrial Area
More informationEuropean Regulatory Experiences and Expectations of HCP Analysis and Control
HCP Strategy Forum, Washington DC, January 26, 2015 www.pei.de European Regulatory Experiences and Expectations of HCP Analysis and Control Blood Products: Dr. Erika Friedl, PEI (DE) Discalimer: The views
More informationRisk Assessments for Host Cell Protein Control Strategies: CDER Experiences
Risk Assessments for Host Cell Protein Control Strategies: CDER Experiences Laurie Graham FDA/CDER Office of Pharmaceutical Quality (OPQ) Office of Policy for Pharmaceutical Quality (OPPQ) 1 Disclaimer
More informationHOST CELL PROTEIN & BIOPROCESSING REAGENT DEVELOPMENT
HOST CELL PROTEIN & BIOPROCESSING REAGENT DEVELOPMENT INTRODUCTION Biopharmaceuticals require products to be free of residual host cell protein (HCP) contaminants from the bioprocessing workflow. To evaluate
More informationStrategies to Improve Drug Tolerance in Nab Assays
Strategies to Improve Drug Tolerance in Nab Assays Steven J Swanson, PhD Senior Vice President, Research ImmunoCellular Therapeutics Ltd steven.swanson@imuc.com AAPS National Biotech Conference June 2015
More informationNew General Chapter on Host Cell Protein Assays (2.6.34)
European Pharmacopoeia Training Session on Biologicals 7-8 February 2017, Strasbourg New General Chapter on Host Cell Protein Assays (2.6.34) Gwenael Cirefice Scientific Officer, European Pharmacopeia
More informationFDA Draft Guidance on Immunogenicity Testing
FDA Draft Guidance on Immunogenicity Testing Susan Kirshner, Ph.D. Associate Chief, Laboratory of Immunology Division of Therapeutic Proteins OBP/CDER/FDA EBF 2010 Guidance for Industry Assay Development
More informationWrap Up Summary CMC Strategy Forum. Bridging Analytical Methods Jan 27, 2014
Wrap Up Summary CMC Strategy Forum Bridging Analytical Methods Jan 27, 2014 Common Messages Industry and Regulatory Method lifecycle includes several elements that occur over time as needed to assure accurate,
More informationRegulatory Perspective on Analytical Method Validation During Product Development
Regulatory Perspective on Analytical Method Validation During Product Development CASSS CMC Strategy Forum 2018 Jacek Cieslak CDER/OPQ/OBP FDA Disclaimer This presentation reflects the views of the author
More informationThe Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives
The Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products CDER/FDA CASSS, Applications of
More informationCHO Host Cell Proteins 3 rd Generation
CHO Host Cell Proteins 3 rd Generation Immunoenzymetric Assay for the Measurement of CHO Host Cell Proteins Catalog # F550 Intended Use This kit is intended for use in determining the presence of host
More informationANALYTICAL VALIDATION CHALLENGES DURING THE RAPID DEVELOPMENT OF KEYTRUDA
ANALYTICAL VALIDATION CHALLENGES DURING THE RAPID DEVELOPMENT OF KEYTRUDA January 29, 2018 CMC Strategy Forum Industry Considerations for Phase-Appropriate Method Validations Athena Nagi Abstract and Outline
More informationRevised Immunogenicity Guideline: Assays and methods- Presentation of the draft guideline and introduction of the topics for discussion
Revised Immunogenicity Guideline: Assays and methods- Presentation of the draft guideline and introduction of the topics for discussion Robin Thorpe & Meenu Wadhwa Revised Guideline: Differences from original
More informationU.S. Pharmacopeia National Formulary. USP 39 Published General Chapter <1132> Residual Host Cell Protein Measurement in Biopharmaceuticals
2016 U.S. Pharmacopeia National Formulary USP 39 NF 34 USP 39 Published General Chapter Residual Host Cell Protein Measurement in Biopharmaceuticals The official version can be found in the USP
More informationImmunogenicity. How to deal with? Nathalie Macé Sanofi, Biomarkers & Biological analyses Unit
Immunogenicity How to deal with? Nathalie Macé Sanofi, Biomarkers & Biological analyses Unit Club Phase I, 22 March 2016 1 Outline Introduction to immunogenicity Analytical challenges for immunogenicity
More informationImmunogenicity of Therapeutic Proteins. Steven J Swanson, Ph.D. Executive Director, Clinical Immunology
Immunogenicity of Therapeutic Proteins Steven J Swanson, Ph.D. Executive Director, Clinical Immunology swanson@amgen.com Causes of Immunogenicity Sequence differences between therapeutic protein and endogenous
More informationHEK 293 Host Cell Proteins 2 nd Generation
HEK 293 Host Cell Proteins 2 nd Generation Immunoenzymetric Assay for the Measurement of HEK 293 Host Cell Proteins Catalog # F650 Intended Use This kit is intended for use in determining the presence
More informationA Regulatory Perspective on Characterization and Control of Process-Related Impurities
A Regulatory Perspective on Characterization and Control of Process-Related Impurities Christopher Downey, PhD FDA/CDER Office of Biotechnology Products CASSS Bay Area Discussion Group June 2017 Disclaimer
More informationA FDA Product Reviewer s Perspective on Building A Quality Dossier
A FDA Product Reviewer s Perspective on Building A Quality Dossier CASSS Mid-West Discussion Group October 29, 2015 University Center of Lake County, Grayslake, IL Howard Anderson, PhD Team Lead Product
More informationVendor Neutral Host Cell Protein Analysis
Vendor Neutral Host Cell Protein Analysis Regulator Positions on HCPs VERY CLEAR Regulators classify residual host cell proteins (HCPs) as process-related impurities [ICH Q6B, Q2B]. Finding, measuring
More informationBIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE
The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate and/or remove potential viral contaminants. Experience and knowledge in selecting
More informationBHK Cell Host Cell Proteins
BHK Cell Host Cell Proteins Immunoenzymetric Assay for the Measurement of Baby Hamster Kidney (BHK) Host Cell Proteins Catalog # F510 Intended Use This kit is intended for use in determining the presence
More informationPeptide libraries: applications, design options and considerations. Laura Geuss, PhD May 5, 2015, 2:00-3:00 pm EST
Peptide libraries: applications, design options and considerations Laura Geuss, PhD May 5, 2015, 2:00-3:00 pm EST Overview 1 2 3 4 5 Introduction Peptide library basics Peptide library design considerations
More informationAdvanced Therapeutic Antibody Discovery with Multiplexed Screening
Advanced Therapeutic Antibody Discovery with Multiplexed Screening White Paper Scientists need powerful tools that can deliver results to fully understand the ability of candidate antibodies to interrupt
More informationSaccharomyces cerevisiae Host Cell Proteins
Saccharomyces cerevisiae Host Cell Proteins Immunoenzymetric Assay for the Measurement of Saccharomyces cerevisiae Host Cell Proteins Catalog # F135 Intended Use This kit is intended for use in determining
More informationA549 Cell Host Cell Proteins
A549 Cell Host Cell Proteins Immunoenzymetric Assay for the Measurement of A549 Host Cell Proteins Catalog # F230 Intended Use This kit is intended for use in determining the presence of protein contamination
More informationChapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology
Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing
More information1. Immunization. What is Immunization? 12/9/2016. Chapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology
Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing
More informationHeLa Host Cell Proteins
HeLa Host Cell Proteins Immunoenzymetric Assay for the Measurement of HeLa Cell Host Cell Proteins Catalog # F810 Intended Use This kit is intended for use in determining the presence host cell protein
More informationOverview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services
Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations Audrey Chang, PhD, Senior Director Development Services Definition of Biologics: PHS Act, section 351 Virus, therapeutic
More informationGyrolab ADA assay protocol
Gyrolab ADA assay protocol Gyrolab ADA assay protocol D0016561/G, June 2017 Table of Contents Abbreviations... 2 Introduction... 2 Prerequisites... 3 Procedure... 4 Gyrolab ADA protocol overview... 4 Without
More informationAssays and Strategies for Immunogenicity Assessment. Steven J Swanson, Ph.D. Executive Director, Medical Sciences Clinical Immunology, Amgen
Assays and Strategies for Immunogenicity Assessment Steven J Swanson, Ph.D. Executive Director, Medical Sciences Clinical Immunology, Amgen General Antibody Assay Strategy Correlation of clinical findings
More informationConnecting People, Science and Regulation
Connecting People, Science and Regulation Bethesda Towers 4350 East West Highway, Ste 600 Bethesda, MD 20814 USA Tel: +1 (301) 656-5900 Fax: +1 (301) 986-0296 www.pda.org PDA Europe ggmbh Am Borsigturm
More informationApplying Affimers. Dr Amanda Nicholl at Avacta Life Sciences. Improving Antibody PK Assay Development
Improving Pharmacokinetic Assays in a Regulatory Bioanalysis Setting Applying Affimers With an increasing number of antibody-based therapeutics entering the clinic, the need for validated anti-idiotypic
More informationCAP cell Host Cell Proteins
CAP cell Host Cell Proteins Immunoenzymetric Assay for the Measurement of CAP cell line Host Cell Proteins Catalog # F820 Intended Use This kit is intended for use in determining the presence of host cell
More informationP. fluorescens Host Cell Proteins
P. fluorescens Host Cell Proteins Immunoenzymetric Assay for the Measurement of Pseudomonas fluorescens Host Cell Proteins Catalog # F450 Intended Use This kit is intended for use in determining the presence
More informationFDA recommendations for comparability studies to support manufacturing changes. Joslyn Brunelle, PhD Office of Biotechnology Products OPQ/CDER/FDA
FDA recommendations for comparability studies to support manufacturing changes Joslyn Brunelle, PhD Office of Biotechnology Products OPQ/CDER/FDA The views and opinions expressed here should not be used
More informationHEK 293 Host Cell Proteins
HEK 293 Host Cell Proteins Immunoenzymetric Assay for the Measurement of HEK 293 Host Cell Proteins Catalog # F650R Intended Use This kit is intended for use in determining the presence host cell protein
More informationRegulatory Challenges for the Licensure of Future Vaccines
Regulatory Challenges for the Licensure of Future Vaccines Tong Wu, Ph.D. Bacterial & Combination Vaccine Division, BGTD, Health Canada June 26-29, 2018, Seoul, Korea, the Global Bio Conference 1 Disclaimer
More informationAnalytical Procedures and Methods Validation for Drugs and Biologics
Final Guidance for Industry Analytical Procedures and Methods Validation for Drugs and Biologics Analytical procedures and Method Validation June 21, 2016 Lokesh Bhattacharyya Chief, LACBRP/DBSQC OCBQ/CBER/FDA
More informationSolutions for Your Research
Solutions for Your Research Custom Antibody Services Polyclonal Monoclonal The service we offer is very complete starting from rabbits, mice and rats. The different formats provided by Primm depend on
More informationPER.C6 cells Host Cell Proteins
PER.C6 cells Host Cell Proteins Immunoenzymetric Assay for the Measurement of PER.C6 cell line Host Cell Proteins Catalog # F530 Intended Use This kit is intended for use in determining the presence of
More informationFDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010
FDA Public Hearing: Approval Pathway for Biosimilar and Interchangeable Biological Products November 2-3, 2010 1 The Biotechnology Industry Organization Over 1,100 members, including biotechnology companies,
More informationStrategies in proteomics
Strategies in proteomics Systems biology - understand cellpathways, network, and complex interacting (includes Genomics, Proteomics, Metabolomics..) Biological processes - characterize protein complexes,
More informationBCH 462. Single Radial Immunodiffusion and Immuno-electrophoresis
BCH 462 Single Radial Immunodiffusion and Immuno-electrophoresis Immunoassays tests include: 1. Precipitation. 2. Agglutination. 3. Immunofluorescence. 4. Radioimmunoassay (RIA). 5. Enzyme-Linked Immuno
More informationBHK Cell Host Cell Proteins
BHK Cell Host Cell Proteins Immunoenzymetric Assay for the Measurement of Baby Hamster Kidney (BHK) Host Cell Proteins Catalog # F510 Intended Use This kit is intended for use in determining the presence
More informationDivision of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852
Reference No.: FDAA10017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 VIA WEB SUBJECT: Approval Pathway for Biosimilar and Interchangeable
More informationVero Cell Host Cell Proteins
Vero Cell Host Cell Proteins Immunoenzymetric Assay for the Measurement of Vero Cell Host Cell Proteins Catalog # F500 Intended Use This kit is intended for use in determining the presence of host cell
More information6 th EBF Open meeting, Barcelona November 21st, 2013
Validation of an immunoassay to selectively quantify the naked antibody of a new Sanofi Antibody Drug Conjugate: an additional tool for improvement of PK interpretation 6 th EBF Open meeting, Barcelona
More informationA Regulator s Perspective on Risk Based and Phase Appropriate Comparability. Marjorie Shapiro, Ph.D. Division of Monoclonal Antibodies OBP, CDER,FDA
A Regulator s Perspective on Risk Based and Phase Appropriate Comparability Marjorie Shapiro, Ph.D. Division of Monoclonal Antibodies OBP, CDER,FDA WCBP 2014 Outline Reasons for Changes Comparability ICH
More informationDr. Earl Dye CMC/GMP Considerations for Expedited Development Programs
Dr. Earl Dye CMC/GMP Considerations for Expedited Development Programs Earl Dye is Director of Technical Regulatory Policy in Genentech s Washington, DC Regulatory Affairs Office, and is the FDA Liaison
More informationRegulatory Considerations on. Office of Biotechnology Products
Regulatory Considerations on Multiproduct t Facilities for Biotechnology Products Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products OPS/CDER/FDA 2011 CASSS CMC Strategy
More informationCustom Antibody Services. Antibodies Designed Just for You. HuCAL Recombinant Monoclonal Antibody Generation Service
Custom Antibody Services Antibodies Designed Just for You HuCAL Recombinant Monoclonal Antibody Generation Service Antibodies Designed Just for You What if there was a technology that would allow you to
More informationChinese Hamster Ovary Host Cell Proteins. Catalog # F015
Cygnus Technologies, Inc. Revision #6-08 Chinese Hamster Ovary Host Cell Proteins Immunoenzymetric Assay for the Measurement of Chinese Hamster Ovary Host Cell Proteins Catalog # F015 Intended Use This
More informationImmunological Applications. Chapter 8: Background
Immunological Applications Chapter 8: Background The Immune System Types of Immunity Innate The natural immunity present at birth Acquired A specific response to foreign substances. Some cells remember
More informationNDA Advisory Services Ltd
Declaration of Interest statement: Paul Chamberlain has received Consulting fees from different companies in respect of strategic and operational advice relating to biopharmaceutical development; he is
More informationFDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer
FDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer Yongjie Zhou, M.D., Ph.D. FDA/CBER/OCTGT/DCEPT Yongjie.zhou@fda.hhs.gov isbtc Global Regulatory Summit October 29, 2008
More informationThe United States Pharmacopeia Strategy on Biotherapeutic Products Standards. Jaap Venema, Ph.D. Chief Science Officer & Chair, Council of Experts
The United States Pharmacopeia Strategy on Biotherapeutic Products Standards Jaap Venema, Ph.D. Chief Science Officer & Chair, Council of Experts U.S. Pharmacopeia Who We Are Scientific, independent, volunteer-driven,
More informationImmunogenicity Assay Strategies for Antibody-Drug Conjugates
Immunogenicity Assay Strategies for Antibody-Drug Conjugates 8th World ADC Conference, San Diego 20 Sep 2017 Seema Kumar, PhD Associate Scientific Director Global Early Development (GED) EMD Serono Research
More informationAntibody Generation: challenges and solutions. Glen Marszalowicz, PHD May 10, AM
Antibody Generation: challenges and solutions Glen Marszalowicz, PHD May 10, 2015 9AM GenScript the most cited biology CRO CRISPR Services Gene Services Peptide Services Protein Services Antibody Services
More informationSubmission preparation what to watch out for
Submission preparation what to watch out for EBF 2017 Boris Gorovits AAPS BIOTEC section Pfizer June 2017 Analytes Commonly Assessed for ADC PK Unconjugated Drug analyte Total Antibody analyte Conjugated
More informationCase Study: A Phase-Driven Approach to the Development and Lifecycle Management of Potency Assays. Spring in New England!!!
Case Study: A Phase-Driven Approach to the Development and Lifecycle Management of Potency Assays CASSS Bioassays 2016: Scientific Approaches & Regulatory Strategies Session Potency Assays: Cell-based
More informationSUBMISSION OF COMMENTS ON GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS - EMEA/CHMP/BWP/398498/2005
20 December 2006 European Medicines Agency (EMEA) 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom SUBMISSION OF COMMENTS ON GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL INVESTIGATIONAL
More informationAAV vectors for gene therapy. Any Gene to Any Cell
AAV vectors for gene therapy Any Gene to Any Cell % Population WHY WORK WITH SIRION? OVERCOME MAJOR ROAD BLOCKS IN AAV GENE THERAPY Invent improved AAV vectors with optimized transduction and expression
More informationSaccharomyces cerevisiae Host Cell Proteins
Saccharomyces cerevisiae Host Cell Proteins Immunoenzymetric Assay for the Measurement of Saccharomyces cerevisiae Host Cell Proteins Catalog # F135 Intended Use This kit is intended for use in determining
More informationRecombinant Antibody Production in Therapeutic Antibody Projects. Keshav Vasanthavada Senior Marketing Specialist, GenScript April 7, 2016
Recombinant Antibody Production in Therapeutic Antibody Projects Keshav Vasanthavada Senior Marketing Specialist, GenScript April 7, 2016 Presentation Outline 1 2 3 4 5 Introduction Recombinant Ab Production
More informationSP 2/0 Host Cell Proteins
SP 2/0 Host Cell Proteins Immunoenzymetric Assay for the Measurement of SP 2/0 Host Cell Proteins Catalog # F180 Intended Use This kit is intended for use in determining the presence of SP 2/0 host cell
More informationBiosimilars China Guideline. Dr Dr Michel Mikhail
Biosimilars China Guideline Dr Dr Michel Mikhail 1 Contents Regulatory context of biologicals in China Decree 28 issued by SFDA October 2007 Proposed biosimilars guideline 10/29/14 Reference drugs to use
More informationMRC5 Host Cell Proteins
MRC5 Host Cell Proteins Immunoenzymetric Assay for the Measurement of MRC5 Host Cell Proteins Catalog # F300 Intended Use This kit is intended for use in determining the presence of MRC5 host cell protein
More informationPER.C6 cells Host Cell Proteins
PER.C6 cells Host Cell Proteins Immunoenzymetric Assay for the Measurement of PER.C6 cell line Host Cell Proteins Catalog # F530 Intended Use This kit is intended for use in determining the presence of
More informationRegulatory perspective on setting clinically relevant specifications. Joslyn Brunelle, PhD Team Leader Office of Biotechnology Products
Regulatory perspective on setting clinically relevant specifications Joslyn Brunelle, PhD Team Leader Office of Biotechnology Products Disclaimer The views and opinions expressed should not be used in
More informationQuality of raw materials and manufacturing of advanced therapies. Fouad Atouf, Ph.D. Head, Global Biologics July 12, 2018
Quality of raw materials and manufacturing of advanced therapies Fouad Atouf, Ph.D. Head, Global Biologics July 12, 2018 Evolution of the compendia 1820: a single recipe book 2018: Procedures and acceptance
More information3D Structure of Biologics in a Convenient Immunoassay Format
3D Structure of Biologics in a Convenient Immunoassay Format Xing Wang, Ph.D. Array Bridge Inc. 5/25/2017 1 Topics Covered Today Why New Technologies? Technology Development. Case Studies for Novel and
More informationEstablished Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry
Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationCASSS CMC Strategy Forum Barcelona, Spain. EBE Satellite Session Comparability Concept Paper 21 st March 2011
CASSS CMC Strategy Forum Barcelona, Spain EBE Satellite Session Comparability Concept Paper 21 st March 2011 Aim of concept paper Points to consider in planning and undertaking of comparability exercise
More informationOpportunities for Accelerating Cell Line Development and Beyond
Opportunities for Accelerating Cell Line Development and Beyond European CM&C Strategy Forum May 24, 2017 Christopher Frye, Ph.D. Research Advisor & Group Leader Bioprocess R&D Presentation Outline CM&C
More informationFind 1 cell in 100,000 with ELISpot
Find 1 cell in 100,000 with ELISpot ELISpot is a sensitive assay used to quantify cytokine- or immunoglobulin-secreting cells at the single-cell level. ELISpot has been widely applied to investigate specific
More informationDevelopment of Multiplex Sensitive Anti-Drug Antibody Assays for CRISPR/Cas9 Gene Therapies
Development of Multiplex Sensitive Anti-Drug Antibody Assays for CRISPR/Cas9 Gene Therapies September 27, 2017 Junxia Wang editasmedicine.com 1 Overview of the presentation Immunogenicity Introduction
More informationComments from: 1. General comments. International Plasma Fractionation Association (IPFA) Our ref. IP
Submission of comments on Commission proposal for Good Manufacturing Practice for Advanced Therapy Medicinal Products Comments from: Name of organisation or individual International
More informationT-cell response. Taken from NIAID: s.aspx
T-cell receptor T-cell response 1. Macrophage or dendritic cell digest antigen bacteria, virus 2. Fragments of Ag bind to major histo-compatiblity (MHC) proteins in macrophage. 3. MHC I-Ag fragment expressed
More informationGuidance for Industry
Guidance for Industry Assay Development for Immunogenicity Testing of Therapeutic Proteins DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
More informationOutcomes of the Global Bioanalysis Consortium s Recommendations: Large Molecule Discussion Topics. Binodh DeSilva on behalf of LM Harmonization Teams
Outcomes of the Global Bioanalysis Consortium s Recommendations: Large Molecule Discussion Topics Binodh DeSilva on behalf of LM Harmonization Teams TEAM LEADS TEAM Team Lead L1 Specific run Acceptance
More informationThe monoclonal antibody (MAb) market
Reimagining Capacity for Today s Purification of Monoclonal Antibodies Jonathan Royce The monoclonal antibody (MAb) market has grown over the past decade to be about half of the biomanufacturing market
More informationApplication of ICH Q12 Tools and Enablers Post-Approval Lifecycle Management Protocols
Joint BWP/QWP/GMDP IWG Industry European Workshop on Lifecycle Management Application of ICH Q12 Tools and Enablers Post-Approval Lifecycle Management Protocols 1 Outline Introduction: evolution of PACMP
More informationSQI Diagnostics Ig_PLEX Assay: Aligned with Immunogenicity Testing FDA and EMA Guidance
SQI Diagnostics Ig_PLEX Assay: Aligned with Immunogenicity Testing FDA and EMA Guidance Jeff Terryberry, Gabriel Armstrong, and Jaymie R Sawyer SQI Diagnostics, Toronto ON Canada, 9-Oct-2012 In the past
More informationYour Antibody Source. prosci-inc.com. Extensive Antibody Services Broad Antibody Catalog
Your Source prosci-inc.com Extensive Services Broad Catalog Company Overview Established in 1998, ProSci Incorporated is a leading provider of high performance antibodies and custom antibody services.
More informationProspector Custom Peptide Libraries
Prospector Custom Peptide Libraries Prospector custom peptide libraries allow the rapid screening of many peptides for bioreactivity. Overlapping peptide libraries can be used to investigate immune responses
More informationA novel approach to Protein A capture chromatography to help decrease cost of clinical manufacturing and reduce supply chain risk
PRODUCT BULLETIN POROS MabCapture A resins A novel approach to Protein A capture chromatography to help decrease cost of clinical manufacturing and reduce supply chain risk Introduction As cell culture
More informationCapillary Electrophoresis Compendial Applications
Capillary Electrophoresis Compendial Applications Anita Szajek, Ph.D. Principal Scientific Liaison, Biologics & Biotechnology 14 th Symposium on the Practical Applications for the Analysis of Proteins,
More informationYour bridge to. better medicines
Your bridge to better medicines At a Glance Anapharm Bioanalytics is a client-oriented, GLP-certified, FDA-inspected, GCP-compliant and ANVISA-certified bioanalytical contract research organization (CRO)
More informationPaving the way for Non-Clinical Bioanalytical Partnerships Louise Angell
Paving the way for Non-Clinical Bioanalytical Partnerships Louise Angell Content Overview of non-clinical immunogenicity testing for biologics Regulatory guidance Bioanalytical considerations Risk based
More informationAntigens & Antibodies II. Polyclonal antibodies vs Monoclonal antibodies
A Brief Review of Antibody Structure A Brief Review of Antibody Structure The basic antibody is a dimer of dimer (2 heavy chain-light chain pairs) composed of repeats of a single structural unit known
More informationProcess Removal of Impurities in Biotech Products
Process Removal of Impurities in Biotech Products CASSS Midwest Regional Forum October 5, 2017 Warren R. Emery Sr. Research Scientist Bioproduct R&D, Eli Lilly and Company Pharmaceutical Process Development
More informationAssays for Immunogenicity: Are We There Yet?
Assays for Immunogenicity: Are We There Yet? Mark Wener, MD Department of Laboratory Medicine & Rheumatology Division Department of Medicine University of Washington Seattle, WA 98195 wener@uw.edu Goals:
More informationReplacing Analytical Methods for Release and Stability Testing CBER Perspective
Replacing Analytical Methods for Release and Stability Testing CBER Perspective Presentation at the CMC Strategy Forum January 27, 2014 Lokesh Bhattacharyya Chief, Lab of Analytical Chemistry and Blood
More informationNeutralising Assay Methodologies
Neutralising Assay Methodologies March 9 th, 2016 EMA workshop on immunogenicity assessment of biotechnology derived therapeutic proteins Shalini Gupta, PhD Amgen Inc. shalinig@amgen.com 1 Key Points About
More informationAntibody Services from GenScript
Services from GenScript www.genscript.com GenScript USA Inc. 860 Centennial Ave., Piscataway, NJ 08854 USA Toll-Free: 1-877-436-7274 Fax: 1-732-210-0262 1-732-855-5878 Academic Services Pharmaceutical
More informationAttend this workshop for less than 900 Euros
Attend this workshop for less than 900 Euros 15-16 May 2014 Amgen BioGenes GmbH Biogen Idec Boehringer Ingelheim Charles River Epivax Genentech Janssen Research & MedImmune Merck & Co Merck Millipore MSD
More information